KR20230137284A - 아쿠아포린 억제제의 약학 조성물 및 이의 제조 방법 - Google Patents

아쿠아포린 억제제의 약학 조성물 및 이의 제조 방법 Download PDF

Info

Publication number
KR20230137284A
KR20230137284A KR1020237007248A KR20237007248A KR20230137284A KR 20230137284 A KR20230137284 A KR 20230137284A KR 1020237007248 A KR1020237007248 A KR 1020237007248A KR 20237007248 A KR20237007248 A KR 20237007248A KR 20230137284 A KR20230137284 A KR 20230137284A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
bis
phenyl
trifluoromethyl
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237007248A
Other languages
English (en)
Korean (ko)
Inventor
용 키안
루이웬 시
에이미 리우
티안 송
얀홍 리우
아이주안 펭
진생 렌
Original Assignee
장쑤 심시어 파마슈티컬 컴퍼니 리미티드
에어로믹스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 장쑤 심시어 파마슈티컬 컴퍼니 리미티드, 에어로믹스, 인코포레이티드 filed Critical 장쑤 심시어 파마슈티컬 컴퍼니 리미티드
Publication of KR20230137284A publication Critical patent/KR20230137284A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237007248A 2020-08-05 2021-08-04 아쿠아포린 억제제의 약학 조성물 및 이의 제조 방법 Pending KR20230137284A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010779964.6 2020-08-05
CN202010779964 2020-08-05
PCT/CN2021/110506 WO2022028459A1 (en) 2020-08-05 2021-08-04 Pharmaceutical composition of aquaporin inhibitor and preparation method thereof

Publications (1)

Publication Number Publication Date
KR20230137284A true KR20230137284A (ko) 2023-10-04

Family

ID=80120008

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237007248A Pending KR20230137284A (ko) 2020-08-05 2021-08-04 아쿠아포린 억제제의 약학 조성물 및 이의 제조 방법

Country Status (12)

Country Link
US (1) US20230293556A1 (https=)
EP (1) EP4192442A4 (https=)
JP (1) JP2023536509A (https=)
KR (1) KR20230137284A (https=)
CN (1) CN117337182A (https=)
AU (1) AU2021323181A1 (https=)
BR (1) BR112023002129A2 (https=)
CA (1) CA3187716A1 (https=)
IL (1) IL300341A (https=)
MX (1) MX2023001493A (https=)
TW (1) TW202228714A (https=)
WO (1) WO2022028459A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
US20160279155A1 (en) 2013-11-06 2016-09-29 Aeromics, Inc. Novel formulations
US11117909B2 (en) 2016-05-13 2021-09-14 Aeromics, Inc. Crystals
WO2024208207A1 (zh) * 2023-04-03 2024-10-10 拜西欧斯（北京）生物技术有限公司 一种双取代萘化合物及其药物组合物和用途
WO2025075479A1 (ko) * 2023-10-04 2025-04-10 이화여자대학교 산학협력단 아쿠아포린 4 억제제의 심방세동 치료 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2488363C (en) * 2002-06-06 2011-01-04 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
WO2008067196A2 (en) * 2006-11-16 2008-06-05 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
WO2013169939A2 (en) * 2012-05-08 2013-11-14 Aeromics, Llc New methods
US20160279155A1 (en) * 2013-11-06 2016-09-29 Aeromics, Inc. Novel formulations
CA2931550C (en) * 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US11117909B2 (en) * 2016-05-13 2021-09-14 Aeromics, Inc. Crystals

Also Published As

Publication number Publication date
JP2023536509A (ja) 2023-08-25
CN117337182A (zh) 2024-01-02
AU2021323181A1 (en) 2023-03-23
IL300341A (en) 2023-04-01
MX2023001493A (es) 2023-06-23
EP4192442A1 (en) 2023-06-14
BR112023002129A2 (pt) 2023-04-18
US20230293556A1 (en) 2023-09-21
TW202228714A (zh) 2022-08-01
CA3187716A1 (en) 2022-02-10
EP4192442A4 (en) 2025-03-19
WO2022028459A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
KR20230137284A (ko) 아쿠아포린 억제제의 약학 조성물 및 이의 제조 방법
CA2234140C (fr) Formulation pharmaceutique lyophilisee stable
AU2007322334B2 (en) Method of drug delivery for bone anabolic protein
EP1180368B1 (en) Freeze dried hgf preparations
RU2770366C2 (ru) Препараты даптомицина
JPH08500104A (ja) 結晶質アミホスチン組成物及びその調製方法並びに使用
HU202761B (en) Process for producing stabilized erythropoietin compositions
SK285650B6 (sk) Vodné prípravky moxifloxacínu a chloridu sodného,spôsob ich výroby a kombinovaný preparát
KR101351668B1 (ko) 신규 에포프로스테놀 제형 및 이의 제조방법
KR960012064B1 (ko) 인터로이킨-2-조성물의 제조방법
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
EP1609481A1 (en) Injectable pharmaceutical compositions comprising sodium diclofenac, beta-cyclodextrin and a polysorbate
EP3013316B1 (en) Stable intravenous formulation
EP4019033B1 (en) Injectable solution comprising a spirofused tetrapeptide an a ph-regulator for treating kappa opioid receptor-associated conditions
JPH10508598A (ja) トロンビン阻害剤を含有する貯蔵安定な輸液用水溶液
WO2017085696A1 (en) Parenteral formulations of melphalan
SK284311B6 (sk) Stabilizované farmaceutické prostriedky založené na chinupristíne a dalfopristíne a spôsob ich prípravy
US20230068866A1 (en) Daptomycin formulation
US20140275122A1 (en) Voriconazole Formulations
WO2017198224A1 (zh) 一种瑞马唑仑的药物组合物
WO2005046699A1 (ja) プロスタグランジン含有凍結乾燥品
JP7720391B2 (ja) フォスフェニトインナトリウム固体組成物、凍結乾燥法、及びその使用
EA026064B1 (ru) Твердая фармацевтическая композиция, полученная с помощью предварительной стадии замораживания и стадии лиофилизации
US20130131089A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
JP2025535575A (ja) バソプレシン製剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902